8-K: FONAR Reports Q2 Fiscal 2026 Results, Merger Price Raised

FONAR Corporation announced its second-quarter fiscal 2026 financial results, showing revenue and net income growth for the quarter, alongside an increased take-private merger offer of $19.00 per share.

Summary

• FONAR Corporation reported its financial results for the second quarter of fiscal 2026, which ended December 31, 2025.
• Total Revenues-Net for the quarter increased by 2% to $25.5 million compared to the prior year's corresponding quarter.
• Net Income for the quarter increased by 15% to $2.5 million compared to the prior year's corresponding quarter.
• Diluted Net Income per Common Share for the quarter increased by 7% to $0.31 compared to the prior year's corresponding quarter.
• For the six-month period ended December 31, 2025, Total Revenues-Net increased by 3% to $51.6 million.
• However, Net Income for the six-month period decreased by 16% to $5.2 million, and Diluted Net Income per Common Share decreased by 11% to $0.66.
• The company announced on December 29, 2025, that a definitive merger agreement for a previously announced "Take Private" offer was signed, increasing the offer price to $19.00 per common share in cash, up from $17.25 per common share offered in July 2025.
• Cash and cash equivalents decreased 6% to $53.0 million at December 31, 2025, from $56.3 million at June 30, 2025.
• Operating Cash Flow for the six-month period decreased 52% to $1.9 million compared to $3.9 million in the prior year.
• The diagnostic imaging management subsidiary, Health Management Company of America (HMCA), continues to grow, managing 45 MRI scanners and achieving its third highest quarterly scan volume in history (54,846 scans).
• A new high-field MRI installed in October 2025 at a Lynbrook, NY site led to a 30% increase in scan volume at that location, reaching 752 scans in January 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, primarily driven by the increased "Take Private" offer price and strong quarterly operational growth in its core diagnostic imaging business, despite some weaker six-month financial metrics and a decline in cash.

Positives

• Quarterly Total Revenues-Net increased 2% to $25.5 million.
• Quarterly Net Income increased 15% to $2.5 million.
• Quarterly Diluted Net Income per Common Share increased 7% to $0.31.
• Six-month Total Revenues-Net increased 3% to $51.6 million.
• Definitive merger agreement signed for a "Take Private" offer with an increased price of $19.00 per common share, up from $17.25.
• HMCA, the primary revenue source, continues to grow, managing 45 MRI scanners.
• HMCA achieved its third highest quarterly scan volume in history with 54,846 scans.
• Installation of a high-field MRI at an existing site in Lynbrook, NY, resulted in a 30% increase in scan volume at that location, from 579 to 752 scans per month.
• Total Assets increased slightly to $217.2 million at December 31, 2025, from $216.9 million at June 30, 2025.
• Total Current Liabilities decreased to $14.4 million at December 31, 2025, from $17.1 million at June 30, 2025.
• Total Liabilities decreased to $54.4 million at December 31, 2025, from $56.8 million at June 30, 2025.
• Total Stockholders Equity increased to $162.9 million at December 31, 2025, from $160.1 million at June 30, 2025.
• The ratio of Total Assets / Total Liabilities improved to 4.0 at December 31, 2025, from 3.8 at June 30, 2024.
• Working Capital increased to $129.3 million at December 31, 2025, from $127.5 million at June 30, 2024.
• Net Book Value Per Common Share increased to $25.69 at December 31, 2025, from $24.68 at December 31, 2024.

Negatives

• Cash and cash equivalents decreased 6% to $53.0 million at December 31, 2025, from $56.3 million at June 30, 2025.
• Six-month Net Income decreased 16% to $5.2 million compared to the prior year's corresponding period.
• Six-month Diluted Net Income per Common Share decreased 11% to $0.66 compared to the prior year's corresponding period.
• Operating Cash Flow for the six-month period decreased 52% to $1.9 million compared to $3.9 million in the prior year.
• Quarterly scan volume was 0.5% lower than the previous quarter.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Merger Agreement.
• The outcome of any legal proceedings that may be instituted against the Company and others following the announcement of the Merger Agreement.
• The inability to complete the proposed Transactions, including the Merger, due to the failure to satisfy any condition to the Closing, including obtaining the Requisite Company Vote and other Closing conditions.
• Risks that the proposed Merger disrupts current plans and operations of the Company.
• Potential difficulties in employee retention as a result of the proposed Transactions.
• Legislative, regulatory, and economic developments.
• Risks related to disruption of management's attention from the Company's ongoing business operations due to the proposed Transactions.
• The effect of the announcement of the proposed Transactions on the Company's relationships with referral sources and vendors, operating results, and business generally.
• Changes in global, regional, or local political, economic, business, competitive, market, regulatory, and other factors, many of which are beyond the Company's control.
• Systemic and structural changes in the healthcare industry.

Future Outlook

The company continues to seek locations where its technology and services can profitably enhance its existing New York and Florida networks. It is also developing new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, specifically the flow of cerebrospinal fluid, which is expected to benefit patients with whiplash or other neck injuries. The consummation of the proposed "Take Private" transaction, including the merger, is a key forward-looking event, subject to various conditions and risks.

Management Comments

• "Our diagnostic imaging management subsidiary, Health Management Company of America (HMCA), the Company’s primary source of revenue and profit, continues to grow." Timothy Damadian, Chairman and CEO.
• "Scan volume in the second quarter of Fiscal 2026 was 54,846, 0.5% lower than that of the previous quarter (55,106), and 3.3% higher than that of the corresponding quarter of Fiscal 2025 and the third highest quarterly scan volume in HMCA history." Timothy Damadian, Chairman and CEO.
• "The addition of second or even third MRI at an existing site also reduces patient backlogs. Doctors know that if they refer their patients to a multi-scanner center managed by HMCA, the patients will get their MRIs completed without delay." Timothy Damadian, Chairman and CEO.
• "We continue to search for locations where the introduction of our technology and services would profitably enhance our existing New York and Florida networks." Timothy Damadian, Chairman and CEO.
• "As always, I remain grateful to our management team and all of our employees for making our company a success." Timothy Damadian, Chairman and CEO.

Industry Context

StockSavvy.ai notes that FONAR operates in the competitive diagnostic imaging sector, where technological advancements and patient access are key drivers. The company's focus on specialized MRI technology, such as the UPRIGHT Multi-Position MRI and new cerebral hydraulics imaging, positions it in a niche segment. The expansion of its HMCA subsidiary and the strategic addition of high-field MRIs at existing sites reflect a trend towards optimizing facility utilization and offering comprehensive imaging solutions to meet diverse patient needs and reduce wait times. The "Take Private" transaction indicates a potential shift in ownership structure, which could impact its long-term strategic direction and market presence.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or industry benchmarks to assess FONAR's financial performance against direct competitors.
• The growth in HMCA's managed MRI scanners from 9 in 2009 to 45 currently suggests a significant expansion in its operational footprint, which could be compared to the growth rates of other diagnostic imaging center operators.
• The 30% increase in scan volume at the Lynbrook site after adding a high-field MRI demonstrates successful integration of new technology and market demand response, a metric that could be benchmarked against similar facility upgrades in the industry.
• The company's unique UPRIGHT Multi-Position MRI and its new works-in-progress technology for cerebral hydraulics represent specialized offerings that differentiate it from standard MRI providers, making direct financial comparisons challenging without specific segment data from competitors.

Legal Proceedings

• Outcome of any legal proceedings that may be instituted against the Company and others following the announcement of the definitive merger agreement for the proposed Take Private transaction.

Related Party Transactions

• Accounts receivable related party: $60 thousand at December 31, 2025.
• Unearned revenue on service contracts related party: $55 thousand at December 31, 2025.
• Prepaid expenses and other current assets related party: $321 thousand at December 31, 2025.
• Note receivable related party: $580 thousand at December 31, 2025.
• Due to related party medical practices: $93 thousand at December 31, 2025.
• Costs related to service and repair fees related parties: $11 thousand for Q2 2026, $19 thousand for 6M 2026.
• Interest income related party: $12 thousand for Q2 2026, $24 thousand for 6M 2026.

Stakeholder Impact

• Shareholders: Will vote on the proposed "Take Private" transaction, which offers $19.00 per common share in cash, an increase from the initial offer. This provides a clear exit strategy and a premium over the initial offer.
• Employees: Potential difficulties in employee retention are a risk mentioned due to the proposed transaction.
• Customers (Patients): Benefit from expanded diagnostic imaging services, including the addition of high-field MRIs and reduced patient backlogs at multi-scanner centers.
• Referral Sources and Vendors: Relationships could be affected by the announcement of the proposed transaction.

Next Steps

• The Company intends to file relevant materials with the SEC, including a proxy statement on Schedule 14A.
• Certain participants in the Transactions intend to jointly file with the SEC a Schedule 13E-3 Transaction Statement.
• Promptly after filing its definitive proxy statement, the Company will mail the definitive proxy statement, the Schedule 13E-3, and a proxy card to each stockholder.
• A special meeting of the Company's stockholders will be held to consider the proposed "Take Private" transaction.
• The company continues to search for locations to expand its New York and Florida networks.
• Continued development of works-in-progress technology for visualizing and quantifying cerebral hydraulics of the central nervous system.

Key Dates

Recommendation

The definitive merger agreement with an increased offer price of $19.00 per share provides a clear valuation for the stock, suggesting limited upside beyond this price unless a higher bid emerges. While the company shows operational growth in its core business, the pending "Take Private" transaction makes long-term investment considerations less relevant. Investors currently holding the stock should hold until the merger is completed to realize the cash offer, while new investors might find better opportunities elsewhere given the capped upside.

Keywords

MRI scanning, Diagnostic imaging, Healthcare technology, Medical devices, Take private merger, Financial results, Quarterly report, FONAR, HMCA, UPRIGHT MRI